Daniel Wanner

Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension

F. Trensz, Céline Bortolamiol, Markus Kramberg et al. · Journal of Pharmacology and Experimental Therapeutics · 2019 · 57 citations · Full text

Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors

Marc Iglarz, Pauline Steiner, Daniel Wanner et al. · Journal of Cardiovascular Pharmacology · 2015 · 50 citations · Full text

Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension

Marc Iglarz, Alexandre Bossu, Daniel Wanner et al. · Life Sciences · 2014 · 43 citations · Full text

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension

Marc Iglarz, Kyle Landskroner, Yasmina Bauer et al. · Journal of Cardiovascular Pharmacology · 2015 · 37 citations · Full text

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential

John Gatfield, Katalin Menyhart, Daniel Wanner et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 35 citations · Full text